Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3-(4-Benzenesulfonyl-Thiophene-2-Sulfonylamino)-Phenylboronic Acid is an experimental small molecule inhibitor belonging to the sulfanilide class of organic compounds. It acts as a potent inhibitor of bacterial beta-lactamase enzymes, including AmpC beta-lactamase from Escherichia coli and Enterobacter cloacae, as well as TEM-type beta-lactamases. The compound binds to the active site of these enzymes and inhibits their function, thereby potentially restoring or enhancing the efficacy of beta-lactam antibiotics against resistant bacteria. Its mechanism involves competitive inhibition at the enzyme's active site with reported Ki values in the nanomolar range for some targets. This compound has not been approved for clinical use and remains at an experimental stage with no known clinical trials or marketed products[1][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-(4-benzenesulfonyl-thiophene-2-sulfonylamino)-phenylboronic acid.